EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 44 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection Study presents an AI-guided approach to target cancer antigens MOST POPULAR A recipe for hydration! August 7, 2020 Recognising the essential role of clinical research nurses October 13, 2021 New Imaging Tool Could Predict Whether Hormone Therapy Will Work in... February 4, 2021 Artificial Intelligence Brings Pancreatic Cancer Screening One Step Closer to Reality... July 2, 2020 Load more HOT NEWS FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ΚΑΡΚΙΝΟΣ ΧΟΛΗΔΟΧΟΥ ΚΥΣΤΕΩΣ Clinical Trials in Genitourinary Cancers: KEYNOTE-641, P3BEP, and PIVOT-09 Discovery of Tumor Suppressor Suggests New Cancer Treatment Strategies
